Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12661111 | 0.83 | CTSK (0.41) | TGFBR1GAA | |
| SCHEMBL890099 | 0.83 | CTSK (0.41) | TGFBR1GAA | |
| SCHEMBL12630385 | 0.83 | CTSK (0.41) | TGFBR1GAA | |
| SCHEMBL627952 | 0.83 | TGFBR1 (0.46) | TGFBR1ALOX15 | |
| SCHEMBL627951 | 0.83 | TGFBR1 (0.46) | TGFBR1ALOX15 | |
| SCHEMBL12661081 | 0.83 | TGFBR1 (0.44) | TGFBR1ALDH1A1ALOX15MGAMGAA | |
| SCHEMBL12977228 | 0.83 | TGFBR1 (0.44) | TGFBR1ALDH1A1ALOX15MGAMGAA | |
| SCHEMBL890149 | 0.82 | GAA (0.32) | ALDH1A1ALOX15GAA | |
| SCHEMBL12061774 | 0.82 | GAA (0.32) | ALDH1A1ALOX15GAA | |
| SCHEMBL12654968 | 0.82 | GAA (0.32) | ALDH1A1ALOX15GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3438106-A1 | ANTI-VIRAL COMPOUNDS | AbbVie Ireland Unlimited Company (IE) | 2019-02-06 | — | — | EP | disclosed |
| US-20170157104-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| US-20170157105-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2017-06-08 | — | — | US | disclosed |
| EP-2678334-B1 | ANTI-VIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2017-03-22 | — | — | EP | disclosed |
| US-9586978-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2017-03-07 | — | — | US | disclosed |
| US-9394279-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-9278922-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150218194-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-08-06 | — | — | US | disclosed |
| US-9006387-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20150087618-A1 | Anti-Viral Compounds | ABBVIE INC. (US) | 2015-03-26 | — | — | US | disclosed |
| US-8937150-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-8921514-B2 | Anti-viral compounds | ABBVIE INC. (US) | 2014-12-30 | — | — | US | disclosed |
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES | 2014-10-23 | — | — | US | disclosed |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. (US) | 2014-06-05 | — | — | US | disclosed |
| EP-2368890-B9 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-10-30 | — | — | EP | disclosed |
| EP-2368890-B1 | Hepatitis C virus inhibitors | ABBVIE BAHAMAS LTD (BS) | 2013-04-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315792-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885ALDH1A1 2858/4885ALOX15 1847/4885 |
| US-20140155382-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885ALDH1A1 2858/4885ALOX15 1847/4885 |
| US-20170157105-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885ALDH1A1 2858/4885ALOX15 1847/4885 |
| US-20170157104-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885ALDH1A1 2858/4885ALOX15 1847/4885 |
| US-20150087618-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885ALDH1A1 2858/4885ALOX15 1847/4885 |
| US-20150218194-A1 | Anti-Viral Compounds | HAVCR2, EIF2AK2, MAVS | TGFBR1 4637/4885ALDH1A1 2858/4885ALOX15 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.